Role of Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor Type 2/neu, and Ki-67 in Surface Epithelial Ovarian Tumors and Its Histopathological Correlation
DOI:
https://doi.org/10.21276/apalm.3499Keywords:
Immunohistochemistry, ER, PR, HER2/neu, KI67, surface epithelial ovarian tumorsAbstract
Background: This study aims to evaluate the expression of estrogen receptor (ER), progesterone receptor (PR), HER-2/neu, and Ki-67 in epithelial ovarian tumors and their correlation with various clinicopathologic variables. Methods: This study included 50 cases of surface epithelial ovarian tumors. Formalin-fixed paraffin-embedded blocks were prepared from the surgical resection specimens. Hematoxylin and Eosin (H & E) stained sections were examined. Appropriate blocks with tumor tissue were selected for immunohistochemical (IHC) analysis. IHC was performed using commercially available monoclonal antibodies for ER, PR, Ki-67, and HER-2/neu. Results: Amongst a total of 50 malignant ovarian tumors encountered, the most common tumor was of the serous type (30 cases, 60%). Expression of ER was mainly noted in the serous and endometrioid type of surface epithelial tumors. Expression of PR was less in comparison to ER. Expression of HER-2/neu was rarely found. Out of the total 50 cases studied, 10 were post-chemotherapy patients. Expression of Ki-67 in post-chemotherapy patients was reduced. Conclusion: ER positivity is seen in most of the serous tumors. Ki-67 nuclear expression should be considered as a prognostic factor. HER-2/neu overexpression is sparse in our study, so further research with a large sample size, followed by gene amplification, is necessary to rule out HER-2/neu expression in surface epithelial ovarian tumors.
References
1. Feng Z, Wen H, Bi R, et al. A clinically applicable molecular classification for high-grade serous ovarian cancer based on hormone receptor expression. Sci Rep. 2016 May 3:6:25408.
2. Khandakar B, Mathur SR, Kumar L. Kumar S, Datta Gupta S, Iyer VK, et al. Tissue biomarkers in prognostication of serous ovarian cancer following neoadjuvant chemotherapy. BioMed research international. 2014 Apr 17:2014.
3. Voutsadakis IA. A systematic review and meta-analysis of hormone receptor expression in low-grade serous ovarian carcinoma. European journal of gynaecology and reproductive biology. 2021 Jan:256:172-178.
4. Sylvia MT, Kumar S, Dasari P. The expression of immunohistochemical markers estrogen receptor, progesterone receptor, Her-2-neu, p53 and Ki-67 in epithelial ovarian tumors and its correlation with clinicopathologic variables. Indian J Pathol Microbiol. 2012 Jan 55(1):33-37.
5. Verma N, Kumar M, Sagar M. Babu S, Singhai A, Singh N, et al. Expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor type 2/neu in surface epithelial ovarian tumors and its clinicohistopathological correlation. Indian J Health Sci Biomed Res. 2018:11:19-24.
6. Naik PS, Deshmukh S, Khandeparkar SG, Joshi A, Babanagare S, Potdar J, et al. Epithelial ovarian tumors: Clinicopathological correlation and immunohistochemical study. J Midlife Health. 2015 Oct-Dec 6(4):178-83.
7. Bhagora R, Malik R. Trichal VK. Expression of estrogen receptor, progesterone receptor and KI 67 in epithelial ovarian tumors and their histopathological correlation. International Journal of Medical Research and Review. 2017 June 5(6):554-562.
8. Pandey V. Mishra J, Potdar PS. A cross-sectional study of immunohistochemical evaluation of surface epithelial ovarian tumors. MGM J Med Sci. 2022:9:84-88.
9. Pils D, Pinter A, Reibenwein J, Alfanz A, Horak P. Schmid BC, et al. In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway. British Journal of Cancer. 2007 Feb;96(3):485-491.
10. Verri E, Guglielmini P, Puntoni M, Perdelli L, Papadia A, Lorenzi P, et al. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study. Oncology. 2005 Jul;68(2-3):154-161.
11. Mahadevappa A, Krishna SM, Vimala MG. Diagnostic and Prognostic Significance of Ki-67 Immunohistochemical Expression in Surface Epithelial Ovarian Carcinoma. J Clin Diagn Res. 2017 Feb;11(2):8-12.
12. Saurabh S, Satpathy PK. Study of surface epithelial ovarian malignancies with reference to their histological grading and ER & Ki-67 immunoreactivity. J. Evid. Based Med. Healthc. 2019;6(34):2276-2280.
13. Luo H, Li S, Zhao M, Sheng B, Zhu H, Zhu X. Prognostic value of progesterone receptor expression in ovarian cancer: a meta-analysis. Oncotarget. 2017 May 30;8(22):36845-36856.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Sapna Shreyas Deshpande, Mohasin Jakirhusain Halgale, Pradnya Manikrao Chimankar, Akshay V Vadavadgi, Vishrabdha Rahul Pawar
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
